MARKET

STTK

STTK

Shattuck Labs, Inc.
NASDAQ
3.770
+0.200
+5.60%
After Hours: 3.633 -0.137 -3.62% 19:24 02/06 EST
OPEN
3.540
PREV CLOSE
3.570
HIGH
3.855
LOW
3.540
VOLUME
419.45K
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
0.6922
MARKET CAP
238.57M
P/E (TTM)
-3.6968
1D
5D
1M
3M
1Y
5Y
1D
Shattuck Labs to Join Piper Sandler Virtual Novel Targets in Immunology Symposium
Reuters · 1d ago
Shattuck Labs Insider Buyers Net US$637k Despite 12% Stock Decline
Simply Wall St · 1d ago
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
Barchart · 1d ago
Shattuck Labs Sets Earlier Date for 2026 Annual Meeting
TipRanks · 1d ago
Weekly Report: what happened at STTK last week (0126-0130)?
Weekly Report · 5d ago
Shattuck earns new Overweight at Piper Sandler ahead of upcoming catalysts
Seeking Alpha · 01/28 17:05
Shattuck Labs Price Target Announced at $15.00/Share by Piper Sandler
Dow Jones · 01/28 14:03
Shattuck Labs initiated with an Overweight at Piper Sandler
TipRanks · 01/28 09:55
More
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Webull offers Shattuck Labs Inc stock information, including NASDAQ: STTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STTK stock methods without spending real money on the virtual paper trading platform.